Abstract
Most viral respiratory tract infections are caused by classic respiratory viruses, including influenza, respiratory syncytial virus, human metapneumovirus, parainfluenza, rhinovirus, and adenovirus, whereas other viruses, such as herpes simplex, cytomegalovirus, and measles virus, can opportunistically affect the respiratory tract. The M2 inhibitors, amantadine and rimantadine, were historically effective for the prevention and treatment of influenza A but all circulating strains are currently resistant to these drugs. Neuraminidase inhibitors are the sole approved class of antivirals to treat influenza. Ribavirin, especially when combined with intravenous antibody, reduces morbidity and mortality among immunosuppressed patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 139-153 |
| Number of pages | 15 |
| Journal | Clinics in Chest Medicine |
| Volume | 38 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 1 2017 |
Funding
Disclosure Statement: M.G. Ison has received research support, paid to Northwestern University, from Alios, Astellas, Beckman Coulter, Chimerix, Gilead, Jansen/Johnson & Johnson; he has provided compensated consultation to Celltrion, Chimerix, Farmark, Genentech/Roche, Toyama/MediVector, and Shionogi, and uncompensated consultation to BioCryst, Biota, Cellex, GlaxoSmithKlein, Romark, NexBio, Theraclone, Unither Virology, and Vertex; he is also a paid member of data and safety monitor boards related to research activity conducted by Astellas, Jansen/Vertex.
Keywords
- Influenza
- Neuraminidase inhibitor
- Respiratory syncytial virus (RSV)
- Respiratory virus
- Ribavirin
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
